Boston Scientific invests $1.5 billion for 34% stake in MiRus

Boston Scientific Corporation

Boston Scientific Corporation

BSX

0.00
  • Boston Scientific invested USD 1.5 billion for an about 34% equity stake in privately held MiRus.
  • The deal includes an exclusive option to acquire the MiRus balloon-expandable TAVR system, subject to additional payments and milestones.
  • Exercising the option would require additional aggregate cash payments totaling USD 3 billion, resulting in 100% ownership of the TAVR business.
  • MiRus recently started its STAR pivotal trial for the SIEGEL TAVR valve in up to 1,025 patients with severe, symptomatic aortic stenosis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boston Scientific Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605180630PR_NEWS_USPR_____PH61429) on May 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.